The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odesa, Ukraine.
Moorfields Eye Hospital Center, Al Marina, Abu Dhabi, United Arab Emirates.
J Ocul Pharmacol Ther. 2020 Mar;36(2):122-125. doi: 10.1089/jop.2019.0080. Epub 2019 Nov 22.
To compare the 24-month efficacy of intravitreal ranibizumab and aflibercept in treatment-naive patients with myopic choroidal neovascularization (CNV). Ninety-six naive patients (97 eyes) with myopic CNV were included in this single-center study. Patients received intravitreal ranibizumab (IVR) or aflibercept (IVA) following a pro re nata regimen (PRN). Fifty patients (50 eyes) received 0.5 mg IVR, 46 patients (47 eyes) received 2.0 mg of IVA. There was no significant between-group difference in mean decimal best-corrected visual acuity (BCVA) ( = 0.6) or mean central retinal thickness (CRT) ( = 0.9) at 24 months. The mean ± standard deviation (SD) BCVA at baseline in the IVR group was 0.21 ± 0.14 and 0.20 ± 0.14 in the IVA group. At month 24, BCVA was 0.43 ± 0.24 ( < 0.001) in the IVR group and 0.41 ± 0.2 ( < 0.001) in the IVA group. Baseline mean ± SD CRT was 318 ± 84 microns in the IVR group and 303 ± 65 microns in the IVA group. At month 24, CRT was 226 ± 31 microns in the IVR group ( < 0.001) and 224 ± 35 microns in the IVA group ( < 0.001). There were no significant differences in the mean number of injections between the IVR group and the IVA group (2.9 ± 1.2 vs. 2.8 ± 1.1), ( = 0.7). Our study demonstrates that ranibizumab and aflibercept in a PRN regimen lead to a significant increase of BCVA and decrease in central foveal thickness in treatment-naive patients with myopic CNV after 24 months.
比较玻璃体内雷珠单抗和阿柏西普治疗初治近视性脉络膜新生血管（CNV）患者的 24 个月疗效。本单中心研究纳入 96 例初治近视性 CNV 患者（97 只眼）。患者接受玻璃体内雷珠单抗（IVR）或阿柏西普（IVA）治疗，治疗方案为按需治疗（PRN）。50 例患者（50 只眼）接受 0.5mg IVR，46 例患者（47 只眼）接受 2.0mg IVA。两组患者 24 个月时平均十进制最佳矫正视力（BCVA）（ = 0.6）或平均中心视网膜厚度（CRT）（ = 0.9）无显著差异。IVR 组患者基线时平均 ± 标准差（SD）BCVA 为 0.21 ± 0.14，IVA 组为 0.20 ± 0.14。24 个月时，IVR 组 BCVA 为 0.43 ± 0.24（ < 0.001），IVA 组为 0.41 ± 0.2（ < 0.001）。IVR 组患者基线时平均 ± SD CRT 为 318 ± 84 微米，IVA 组为 303 ± 65 微米。24 个月时，IVR 组 CRT 为 226 ± 31 微米（ < 0.001），IVA 组为 224 ± 35 微米（ < 0.001）。IVR 组和 IVA 组患者平均注射次数无显著差异（2.9 ± 1.2 比 2.8 ± 1.1），（ = 0.7）。本研究表明，在 PRN 方案下，雷珠单抗和阿柏西普治疗初治近视性 CNV 患者 24 个月后可显著提高 BCVA，降低中心凹视网膜厚度。
